On December 14, the investment community reported that Hunan Chenchen Pharmaceutical Technology had been completedRMB A round of financing, byMetaSheng Venture Capital led the investment, followed by Misawa Venture Capital and Jinyu Bogor。This financing will comprehensively accelerate the company's high-quality product research and development and capacity expansion, and always maintain product competitiveness and core technology advantages in the future more fierce competition.
Chenchen Pharma was officially launched in April 2020, and the founding team has been engaged in drug research and development for more than ten years.
The initial business of Chenchen Pharmaceutical is pharmaceutical CRO services. While the CRO business is developing steadily, Chenchen Pharma is also actively exploring new businesses and seeking the second curve of growth. Relying on the advantages of high-level pharmaceutical R&D technical team and cutting-edge equipment, with the goal of solving the quality pain points of difficult raw materials, we strive to develop high-quality biomedical upstream raw materials. The business scope has expanded from high-level technical services to high-quality product development, forming a pattern of dual main businesses of biomedical CRO services and high-quality upstream raw materials. At present, the product pipeline has been expanded to upstream raw materials for biomedicine and in vitro diagnostics, life science reagents and other fields, and has formed a complete product line in GLP-1 drug side chain, monodisperse PEG linker, small nucleic acid delivery galnac and solid phase carrier linker, ultra-high purity nucleotide raw materials (mRNA cap analogues, NTPS, dntps, etc.), biofluorescent dye reagents, etc.
Dr. Lin Yi, Managing Partner of Yuansheng Venture CapitalSaid: China's upstream core raw materials of biomedicine have long relied on imported brands, and domestic substitution has become the general trend in recent years. The core team of Chenchen led by Liu Bo has worked together for many years, with tacit understanding, and has rich capabilities in the synthesis, separation, analysis and identification of small molecule compounds, starting from CRO services, helping the clinical registration and declaration of a number of generic drugs, and at the same time, the company has applied this ability to the R&D and production of upstream core raw material products of biomedicine and in vitro diagnostics, and has successfully developed peptide drug side chains, nucleic acid drug raw materials, fluorescent dyes, monodisperse PEG linkers and other products, which have been widely recognized by customers. Based on the execution capabilities and R&D technical capabilities of the Chenchen Pharmaceutical team, Yuansheng Venture Capital will also use its own resources to help the company explore domestic and foreign markets and help Chenchen Pharmaceutical become a platform enterprise of core raw materials in the upstream of global biomedicine.
Dr. Jiazhi Xia, Partner of Misawa Venture CapitalHe said: Chenchen Pharmaceutical's professionalism and strength in the field of biomedicine are impressive, especially its analysis and separation technology platform has outstanding advantages, which can provide sufficient quality research support for the development of high-quality products, provide "precise navigation" for process development, and improve development efficiency. In particular, GLP-1 drug side-chain products have achieved industry-leading level in terms of quality and cost, and the comprehensive and meticulous quality research work is amazing. Chenchen Pharmaceutical's attention to product quality and breakthroughs in core technologies will win them a competitive advantage that is difficult to imitate.
Li Hongsen, partner of Jinyu BogorHe said: Jinyu Bogor Medical Team has long focused on investment in the field of medical and pharmaceutical upstream chain, and Chenchen Pharmaceutical, as a rising star in the industry, has shown super chemical capabilities, especially good at solving chemical problems in biopharmaceuticals, such as difficult linker, peptide side chain modification, nucleic acid drug raw materials and other sectors. The team led by Dr. Liu has strong execution and operational capabilities, especially focusing on the company's cash flow and profitability, and has always maintained good cash flow and growth since the beginning of the business, which is particularly valuable in the current market situation.